This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Availability of data and materials
All data supporting our findings are contained within the manuscript.
Fernandez-Fernandez B, Sarafidis P, Kanbay M, Navarro-González JF, Soler MJ, Górriz JL, Ortiz A. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Clin Kidney J. 2020;13(5):728–33.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC. DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.
Heerspink HJL, Cherney D, Postmus D, Stefánsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD, Wheeler DC. DAPA-CKD Trial committees and investigators. A pre-specified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int. 2022;101(1):174–84.
Conflict of interest
All authors have nothing to disclose.
This study was approved by the ethics review board of the Jikei University School of Medicine [34–056 (11201)] and conducted according to the Declaration of Helsinki.
Dapagliflozin is approved by the Ministry of Health, Labour and Welfare in Japan and can be used in daily clinical practice, regardless of the CKD stage. Since this was a retrospective observational study, informed consent from the subjects was not required. In addition, the need for written informed consent has been waived in accordance with the Institutional Review Board of the Jikei University School of Medicine and the “Ethical Guidelines for Research on Medicine and Medical Technology Involving Human Subjects”.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
About this article
Cite this article
Matsumoto, K., Ueda, H., Tsuboi, N. et al. Dapagliflozin and the initial glomerular filtration rate decline in advanced-stage non-diabetic chronic kidney disease. Clin Exp Nephrol 26, 1242–1243 (2022). https://doi.org/10.1007/s10157-022-02260-7